Company Overview of YM BioSciences USA Inc.
YM BioSciences USA Inc. develops, acquires, and commercializes products for the treatment of cancer, cancer-related disorders, and infectious diseases. Its portfolio includes therapeutic oncology products, including THYMITAQ, a nolatrexed dihydrochloride for the treatment of patients with inoperable primary liver cancer; and ORATAQ, an oral form of nolatrexed. It was formerly known as EXIMIAS Pharmaceutical Corporation and changed its name to YM BioSciences USA Inc. in May 2006. The company was founded in 1998 and is based in Winchester, Massachusetts. As of May 9, 2006, YM BioSciences USA Inc. operates as a subsidiary of YM BioSciences Inc.
10 Priscilla Lane
Winchester, MA 01890
Founded in 1998
Key Executives for YM BioSciences USA Inc.
Similar Private Companies By Industry
|GlaxoSmithKline Holdings (Americas) Inc.||United States|
|OSR Solutions, Inc.||United States|
|iTherX, Inc.||United States|
|The Lauridsen Group, Inc.||United States|
|Triax Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact YM BioSciences USA Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.